Preoperative Nivolumab Plus Bevacizumab Combined With Chemotherapy Before Surgery in Patients With pMMR/MSS Colorectal Cancer Liver Metastases

Colorectal Cancer Liver Metastases Clinical Trial

Official title:
Safety and Efficacy of Nivolumab Combined With CAPOX Plus Bevacizumab as Neoadjuvant Treatment of pMMR/MSS Colorectal Cancer Liver Metastases Patients：a Single-arm, Phase II, Prospective Study

Status Not yet recruiting

Clinical Trial Summary

This prospective, single-arm study aims to investigate the safety and efficacy of Nivolumab plus bevacizumab and chemotherapy as neoadjuvant treatment in pMMR/MSS Colorectal cancer liver metastases patients

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT05588297
Study type	Interventional
Source	Shanghai Changzheng Hospital
Contact	Haiyang Zhou, MD
Phone	+86 13764515639
Email	haiyang1985_1@aliyun.com
Status	Not yet recruiting
Phase	Phase 2
Start date	October 2022
Completion date	October 2025

View Details

See also
Status	Clinical Trial	Phase
Active, not recruiting	`NCT04272931` - DRAGON 1- Training, Accreditation, Implementation and Safety Evaluation of Combined PVE/HVE	N/A
Completed	`NCT02086656` - PERIOPERATIVE TREATMENT WITH COI-B (CAPECITABINE, OXALIPLATIN, IRINOTECAN AND BEVACIZUMAB) OF HIGH RISK OR BORDERLINE RESECTABLE COLORECTAL CANCER LIVER METASTASES	Phase 2
Recruiting	`NCT05794971` - Regorafenib Combined With Irinotecan Drug-Eluting Beads for Colorectal Cancer Liver Metastases	Phase 3
Not yet recruiting	`NCT05873972` - Multimodal Model for Efficacy Prediction Cetuximab in Colorectal Cancer Liver Metastasis Patient	N/A
Recruiting	`NCT05485909` - Phase II Study of Regorafenib and Toripalimab Combined With RFA in Patients With CRCLM	Phase 2
Active, not recruiting	`NCT03326791` - Aspirin in Colorectal Cancer Liver Metastases	Phase 2/Phase 3